



Clinical Report

Neonatal erythroderma and immunodysplasia: Overlap of cartilage-hair hypoplasia and Omenn syndrome

Anna Insalaco^{a,*}, Cecilia Rossi^b, Emma Bertucci^c, Chiara Fiorentini^d, Annarosa Soresina^e, Silvia Giliani^f, Fulvio Porta^g, Alberto Berardi^a, Licia Lugli^b

^a Post-graduated School of Pediatrics, Department of Medical and Surgical Sciences for Mother, Children and Adults, University of Modena and Reggio Emilia, Italy

^b Neonatology Unit, Mother-Child Department, University Hospital of Modena, Italy

^c Prenatal Medicine Center, Obstetric-Gynecology Unit, Mother-Child Department, University Hospital of Modena, Italy

^d Dermatologic Surgery Unit, University Hospital of Modena, Italy

^e Pediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, University of Brescia and ASST-Spedali Civili di Brescia, Brescia, Italy

^f Cytogenetic and Medical Genetics Unit, "A. Nocivelli" Institute for Molecular Medicine, Spedali Civili Hospital, Brescia, Italy

^g Pediatric Onco-hematology and Bone Marrow Transplant Unit, Children's Hospital, Spedali Civili, Brescia, Italy

ARTICLE INFO

Keywords:

Skeletal dysplasia

Cartilage hair hypoplasia

Neonatal Erythroderma

RNase mitochondrial RNA processing

endoribonuclease

Severe combined immunodeficiency

Omenn syndrome

Case report

ABSTRACT

Cartilage hair hypoplasia (CHH) syndrome (OMIM #250250) is a rare autosomal recessive metaphyseal dysplasia, characterized by disproportionate short stature, hypotrichosis and variable extra-skeletal manifestations, including immunodeficiency, anemia, intestinal diseases, and predisposition to malignancies.

CHH results from homozygous or compound heterozygous mutations in the *RMRP* gene on chromosome 9p13, which encodes an untranslated RNA component of mitochondrial RNA-processing endoribonuclease.

RMRP pathogenic variants can also lead to Omenn Syndrome (OS) (OMIM #603554), a systemic inflammatory condition displaying neonatal erythroderma and immunodeficiency.

This report highlights the genotypic and phenotypic overlap between CHH and OS, by presenting a newborn with skeletal dysplasia, immunodeficiency and neonatal onset erythroderma, carrying the homozygous NR_003051:n.35C > A variant in the *RMRP* gene.

1. Introduction

Cartilage Hair Hypoplasia (CHH) (OMIM #250250) is a rare autosomal recessive skeletal dysplasia due to mutations in the mitochondrial RNA-processing endoribonuclease gene (*RMRP*; MIM *157660), located on chromosome 9p13-p12 and encoding the RNA component of the RNase MRP (ribonuclease mitochondrial RNA processing) complex. This small nucleolar RNA (snoRNA) plays a key role in the cleavage of 5.8S rRNA for ribosome assembly, in the processing of cyclin B mRNA, and interaction with the human telomerase catalytic subunit (hTERT) (Ridanpää et al., 2001; Hermanns et al., 2005; Maida et al., 2009). *RMRP* dysfunction impairs cell proliferation and differentiation, mostly affecting rapidly dividing cells such as lymphocytes and chondrocytes (Thiel et al., 2005; Vakkilainen et al., 2019a).

CHH has a broad phenotype, primarily characterized by disproportionate short stature with skeletal deformities, and hypotrichosis. Extra-

skeletal manifestations range from variable degrees of immunodeficiency and bone marrow dysplasia to conditions such as Hirschsprung's disease (Rider et al., 2009; Kostjukovits et al., 2017; Mäkitie and Kaitila, 1993).

The clinical course and prognosis of CHH patients is mainly determined by the severity of immune dysfunction and by the increased risk of malignancies (Bordon et al., 2010; Ip et al., 2015).

Neonatal erythroderma (NE) is a rare condition defined as widespread redness and inflammation of the skin, covering at least 90 % of the body surface (Ott, 2019). Congenital ichthyoses, primary immunodeficiencies (PIDs), metabolic and genetic disorders, drug use and cutaneous infections are the main causes of NE (Al-Dhalimi, 2007; Pruszkowski et al., 2000). Erythroderma is one of the typical manifestations of Omenn syndrome (OS), an inflammatory condition characterized by skin manifestations, alopecia, chronic diarrhea, failure to thrive, lymphadenopathy, hepatosplenomegaly, and severe combined

* Corresponding author. Via del Pozzo 71, 41124, Modena, Italy.

E-mail address: insalacoanna@gmail.com (A. Insalaco).

<https://doi.org/10.1016/j.ejmg.2026.105069>

Received 12 March 2025; Received in revised form 2 September 2025; Accepted 26 January 2026

Available online 28 January 2026

1769-7212/© 2026 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

immunodeficiency (SCID). Rather than a distinct form of SCID, OS is an inflammatory phenotype that can be associated with genetically different SCIDs. Although OS is not caused by a defined genetic defect, the majority of OS cases reported to date are due to hypomorphic mutations in *RAG1* (MIM*179615) and *RAG2* (MIM*179616) genes, but mutations in other genes (*ADA*, *IL2RG*, *IL7RA*, *DCLRE1C*, *CHD7*, *LIG4* and *RMRP*) are also reported (Dvorak et al., 2023).

To add further details to the knowledge of both the phenotypic spectrum of CHH and OS, we report on a newborn with skeletal dysplasia presenting impressive erythroderma at birth and carrying the homozygous *RMRP* c.35C > A pathogenic variant.

2. Clinical report

The proband is the third daughter of healthy consanguineous (second cousins) parents. Since the 19th week of gestation skeletal dysplasia was suspected because of micromelia (femur length: 23.5 mm; -2.84 DS) and a small thorax. Prenatal invasive diagnostic tests were refused by the parents.

The infant was born at 34weeks' gestation by caesarean section because of preterm labor and breech presentation. She needed resuscitation and admission to the Neonatal Intensive Care Unit for respiratory support. The Apgar score was 2, 7 and 8 at first, fifth and tenth minute, respectively.

At birth her auxological data were: weight 2130 g (38th centile; -0.30 DS), length 40 cm (<1 st centile; -2.59 DS), and head circumference 33 cm (89th centile; 1.28 DS) (Villar et al., 2014).

The proband presented with rhizomelic limb shortening and striking cutaneous manifestations, including severe erythroderma and edematous skin (Fig. 1). Progressive hair and eyebrows loss became evident from the first week of life. Skeletal X-ray confirmed rhizomelia and dumbbell shaped femurs (Fig. 2). Congenital infections were excluded.

She also developed hepatosplenomegaly and lymphadenopathy.

Furthermore, the infant developed anemia requiring blood transfusion, severe hypereosinophilia with normal IgE and progressive lymphopenia. On day 30 she presented multiple bacterial sepsis treated with antibiotics.

In the suspicion of immunodeficiency, a comprehensive immunological workup was performed (Table 1). Immunophenotype analysis revealed reduced lymphocyte T proliferation rate and absence of recent maturation stage T lymphocytes with expansion of the effector component. Additionally, B lymphocytes low levels, predominantly within the unswitched component, hypogammaglobulinemia were observed. Maternal engraftment was excluded. As a result, a diagnosis of T-B-NK + severe combined immunodeficiency (SCID) in a patient with clinical features of Omenn Syndrome (OS) was established.

Treatment with intravenous immunoglobulins, along with broad-spectrum antiviral, antibiotic, and antifungal prophylaxis were started. A haploidentical hematopoietic stem cell transplant was performed when the patient was two months old. Anyway, the child died at 20 months of age. Fig. 3 illustrates the child's growth trajectory during the first months of life.

Several genetic tests were performed: karyotype was 46 XX, normal, and genomic microarray analysis revealed no detectable copy number variations.

The next-generation panel for SCID identified NR 003051:n.35C > A as a homozygous pathogenic variant in the *RMRP* gene, confirming the diagnosis of OS in a patient affected by CHH. Parents were heterozygous for the same mutation. The NR 003051:n.35C > A *RMRP* pathogenic variant was submitted to ClinVar (SUB15583466).

3. Discussion

In this report, we describe a rare presentation of CHH with neonatal



Fig. 1. Erythrodermal and desquamative lesions (A). Hair hypoplasia with eyebrows and eyelashes involvement (B).




Fig. 2. A: at birth skeleton X-ray shows shortened long bones and dumbbell-shaped femurs. 2B: Bell shaped thorax, with no spine nor skull anomalies.

Table 1
Humoral and cellular immunity tests.

Serum immunoglobulins (mg/dL)	Patient Values	Reference Values ^b
IgG	137	598–1672
IgA	1	0–5
IgM	43	5–15
IgE (UI/mL)	3	
Lymphocyte Subset	Patient Values	Reference Values ^b
CD3 ⁺ , cells per μ L	1703	2908–5961
CD3 ⁺ CD4 ⁺ , %	57.8	29.9–64.7
HLA antigen DR+	36.2	0.8–6.1
Naïve	0	68.8–91.7
Effector memory	85.6	1.5–8.3
CD3 ⁺ CD8 ⁺ , %	23.1	9.1–26.9
HLA antigen DR+	39.8	1.6–30.2
Naïve	0	37.9–90.7
Effector memory	81.9	1.3–27.2
CD19 ⁺ , %	4.1	11.2–33.2
CD3 ⁺ CD56 ⁺ CD16 ⁺ , cells per μ L	130	273–1698
TRECs	213/mL	>32028/mL
KRECs	24215/mL	>93810/mL
Mitogenic responses ^a	Patient vs control specimen	
PHA	1.3 vs 1.8	
Anti-CD3	1.2 vs 2.3	

^a Mitogenic responses are expressed as the stimulation index.
^b Reference values are presented as 10th and 90th percentiles based on established values for infants 0–12 months old. Abbreviations: PHA = phytohemagglutinin; TRECs = T-cell receptor excision circles; KRECs = kappa-deleting recombination excision circles.

erythroderma and immunodeficiency.

The newborn exhibited typical features of CHH, including rhizomelic dwarfism, short tubular bones, metaphyseal dysplasia with widened and flared distal metaphyses, and mildly bowed femora, together with hair hypoplasia. Simultaneously, there were features such as erythroderma, SCID, hypereosinophilia, lymphadenopathy, and hepatosplenomegaly,

which are part of the OS spectrum. Therefore, this clinical report highlights a significant phenotypic overlap between CHH and OS. However, the presence of skeletal dysplasia since the prenatal period, associated with a known *RMRP* homozygous pathogenic variant, led us to conclude that OS developed in this patient with genetically confirmed CHH (Ip et al., 2015; Lugli et al., 2021).

CHH is part of the broader CHH-anauxetic dysplasia (CHH-AD) and Supplementary Table 1 provides a comprehensive summary of its clinical and radiological features (Mäkitie et al., 1993). The immunological phenotype of CHH is highly variable, ranging from mild immunodeficiency to SCID, with some patients experiencing a progressive worsening of immunodeficiency over time (Vakkilainen et al., 2019b, 2020). Cell-mediated immunity is often impaired, with decreased lymphocyte proliferation responses in the majority of patients (Rider et al., 2009; Mäkitie and Kaitila, 1993; Vakkilainen et al., 2020; Mäkitie et al., 1995, 1998). Combined immunodeficiency has been reported in 24 % of individuals with CHH, with some of them presenting clinical features of OS (Vakkilainen et al., 2019b; Roifman et al., 2006).

OS represents a unique inflammatory phenotype that can be associated with various genetically diverse forms of SCID. It is characterized by severe immunodeficiency and features of immune dysregulation, such as early-onset erythroderma, hepatosplenomegaly, lymphadenopathy, alopecia, and chronic diarrhea (Omenn, 1965). Although most cases reported to date involve hypomorphic mutations in the *RAG1* and *RAG2* genes, OS is not caused by a single, well-defined genetic defect. Patients with OS associated with *RMRP* pathogenic variants have been previously reported, and their features are summarized in Table 2 (Dvorak et al., 2023; Greenberg-Kushnir et al., 2020).

In some of them, the diagnosis of CHH was delayed and was only recognized after the lack of catch-up growth following bone marrow transplantation (BMT) (Roifman et al., 2006).

Interestingly two patients presented OS without confirmed skeletal dysplasia, confirming the extreme phenotypic variability in patients with *RMRP* mutations (Kavadas et al., 2008).

Even if erythroderma was reported in all the patients with OS carrying *RMRP* mutations, to the best of our knowledge, the current patient is the first presenting erythroderma at birth.




Fig. 3. Post-natal growth chart for length (3A) and weight (3B). INTERGROWTH-21ST Preterm Postnatal Growth Charts are used (Villar J 2015).

Table 2

Previously described patients with OS due to RMRP mutations, compared to our patient.

	Kavadas et al., 2008 (Kavadas et al., 2008)				Ip et al., 2015 (Ip et al., 2015)	Present paper
	Patient 1 ^b	Patient 2 ^b	Patient 3	Patient 4	Patient 5	Proband
General features						
Age (mo)	5	3	3.5	2.5	5	At birth
Sex	F	F	M	F	F	F
Gestational age	At term	At term	NR	NR	NR	34 + 3
Birth length cm (DS)	NR	NR	NR	NR	NR ^a	40 (−2.6)
Growth^a						
Height percentile	<3rd	<3rd	<3rd	<3rd	≤0.4	<1st
Weight percentile	<3rd	<3rd	<3rd	<3rd	NR	38th
Clinical features						
Failure to thrive	+	+	+	+	+	NA
Absent or sparse hair	+	+	+	−	+	+
Short limbs	+	+	+	+	+	+
Erythroderma	Severe	Mild	Severe	Severe	Yes	Severe
Lymphadenopathy	+	+	+	+	+	−
Hepatomegaly	+	+	+	+	+	+
Splenomegaly	+	+	+	NR	+	+
Recurrent infections	+	+	+	+	−	Staphylococcus Aureus, Enterococcus Faecalis and Acinetobacter Baumannii sepsis
	<i>P. Jiroveci</i>	<i>P. Jiroveci</i>				
Protract/recurrent diarrhea	+	+	−	+	+	−
Immunodeficiency						
	T-/B-/NK + SCID	T-/B-/NK- SCID	T-/B-/NK + SCID	T-/B-/NK + SCID		T-/B-/NK + SCID
	Poor T-cell mitogenic response	Poor T-cell mitogenic response	Poor T-cell mitogenic response	Poor T-cell mitogenic response		Poor T-cell mitogenic response
	Oligoclonal expansion of lymphocyte T		Oligoclonal expansion of lymphocyte T			
CHH typical radiological findings						
	+	+	No evidence of metaphyseal dysplasia	No evidence of metaphyseal dysplasia	+	+
RMRP mutations						
Allele 1	TACTCTGTGAAGTACTCTG	ATCTGTG at −13 (insertion)	−25_11dup	−25_13dup	25_11 dup	35 C > A
	TGAAGCTGA at −10 (insertion)					
Allele 2	4 C > T	240 A > C	154 G > C	^b 5 T > C	4 C > T	35 C > A
Outcome						
	Alive and well 14 years after BMT	Alive and well 22 years after BMT	Alive and well 1.5 years after BMT	Alive and well 9 years after BMT	Alive and well 50 months after BMT	Died 20 months after BMT

at diagnosis.

firstly described by Roifman et al., 2006). ° Height persistently <3rd percentile after Bone Marrow Transplantation.

Disproportionate short stature at birth. **Abbreviations:** BMT = **Bone Marrow Transplantation**, NR = **Not reported**; NA = **Not applicable**.

The pre-natal suspicion of skeletal dysplasia and the short-limb dwarfism along with characteristic radiological findings at birth, strongly suggested the diagnosis of CHH early on.

From a genetic perspective, all previously described patients with OS and RMRP mutations were compound heterozygotes, with insertions or duplications in the promoter region on one allele and point mutations in the transcribed region, on the other.

As previously reported, mutations in the promoter region directly reduce RMRP RNA levels, and homozygous variants in this region are rarely reported, suggesting that the complete absence of RMRP is incompatible with life. In contrast, mutations in the transcribed region alter the RNA's secondary structure, leading to decreased stability or reduced enzymatic activity of the RNase MRP complex (Ridanpää et al., 2001; Kavadas et al., 2008; Tan et al., 2023; Vatanavicharn et al., 2010;

Mattijssen et al., 2010; Nakashima et al., 2007).

Our patient, carrying the homozygous NR 003051:n.35C > A RMRP variant in the transcribed region, is the first presenting OS with no alterations in the promoter region.

The homozygous NR 003051:n.35C > A mutation was first reported by Ip et al. in four South-Asian siblings. Among them, three presented with combined or severe combined immunodeficiency, while only two showed radiological features of skeletal dysplasia, underlining once again the high intra-familial phenotypic variability of RMRP mutations (Ip et al., 2015).

4. Conclusions

The unique clinical-instrumental phenotype (skeletal dysplasia with erythroderma, hyper-eosinophilia and SCID) associated with the homozygous NR 003051:n.35C > A pathogenic variant, lead us to the diagnosis of OS in a patient affected by CHH.

This report contributes to expanding the broad phenotypic spectrum of CHH disease, suggesting the potential of early skin involvement, particularly in case of severe immunodeficiency. Even if a certain overlap with OS and CHH has been already described, this case reinforces the link between these two conditions and suggests the importance of a comprehensive immunologic and genetic workup, including RMRP gene, in newborns presenting erythroderma.

CRedit authorship contribution statement

Anna Insalaco: Conceptualization, Data curation, Writing – original draft. **Cecilia Rossi:** Conceptualization, Investigation, Supervision, Validation, Visualization, Writing – review & editing. **Emma Bertucci:** Conceptualization, Investigation, Validation, Visualization, Writing – review & editing. **Chiara Fiorentini:** Conceptualization, Investigation, Validation, Visualization, Writing – review & editing. **Annarosa Sor-esina:** Investigation, Validation, Visualization, Writing – review & editing. **Silvia Giliani:** Investigation, Validation, Visualization, Writing – review & editing. **Fulvio Porta:** Investigation, Validation, Visualization, Writing – review & editing. **Alberto Berardi:** Conceptualization, Investigation, Supervision, Validation, Visualization, Writing – review & editing. **Licia Lugli:** Conceptualization, Data curation, Investigation, Methodology, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ejmg.2026.105069>.

Data availability

The data that has been used is confidential.

References

- Al-Dhalimi, M.A.A., 2007. Neonatal and infantile erythroderma: a clinical and follow-up study of 42 cases. *J. Dermatol.* 34 (5), 302–307.
- Bordon, V., Gennery, A.R., Slatter, M.A., Vandercruys, E., Laureys, G., Veys, P., et al., 2010. Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation. *Blood* 116 (1), 27–35.
- Dvorak, C.C., Haddad, E., Heimall, J., Dunn, E., Buckley, R.H., Kohn, D.B., et al., 2023. The diagnosis of severe combined immunodeficiency (SCID): the primary immune deficiency treatment consortium (PIDTC) 2022 definitions. *J. Allergy Clin. Immunol.* 151 (2), 539–546.
- Greenberg-Kushnir, N., Lee, Y.N., Simon, A.J., Lev, A., Marcus, N., Abuzaitoun, O., et al., 2020. A large cohort of RAG1/2-Deficient SCID patients-clinical, immunological, and prognostic analysis. *J. Clin. Immunol.* 40 (1), 211–222.
- Hermanns, P., Bertuch, A.A., Bertin, T.K., Dawson, B., Schmitt, M.E., Shaw, C., et al., 2005. Consequences of mutations in the non-coding RMRP RNA in cartilage-hair hypoplasia. *Hum. Mol. Genet.* 14 (23), 3723–3740.

- Ip, W., Gaspar, H.B., Kleta, R., Chanudet, E., Bacchelli, C., Pitts, A., et al., 2015. Variable phenotype of severe immunodeficiencies associated with RMRP gene mutations. *J. Clin. Immunol.* 35 (2), 147–157.
- Kavadas, F.D., Giliani, S., Gu, Y., Mazzolari, E., Bates, A., Pegoi, E., et al., 2008. Variability of clinical and laboratory features among patients with ribonuclease mitochondrial RNA processing endoribonuclease gene mutations. *J. Allergy Clin. Immunol.* 122 (6), 1178–1184.
- Kostjukovits, S., Klemetti, P., Valt, H., Martelius, T., Notarangelo, L.D., Seppänen, M., et al., 2017. Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia. *J. Allergy Clin. Immunol.* 140 (2), 612–614.e5.
- Lugli, L., Gancia, S., Bertucci, E., Lucaccioni, L., Calabrese, O., Madeo, S., et al., 2021. Homozygous n.64C>T mutation in mitochondrial RNA-processing endoribonuclease gene causes cartilage hair hypoplasia syndrome in two siblings. *Eur. J. Med. Genet.* 64 (2), 104136.
- Maida, Y., Yasukawa, M., Furuuchi, M., Lassmann, T., Possemato, R., Okamoto, N., et al., 2009. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. *Nature* 461 (7261), 230–235.
- Mattijssen, S., Welting, T.J.M., Pruijn, G.J.M., 2010. RNase MRP and disease. *Wiley Interdiscip. Rev. RNA* 1 (1), 102–116.
- Mäkitie, O., Kaitila, I., Savilahti, E., 1998. Susceptibility to infections and in vitro humore functions in cartilage-hair hypoplasia. *Eur. J. Pediatr.* 157 (10), 816–820.
- Mäkitie, O., Sulisalo, T., de la Chapelle, A., Kaitila, I., 1995. Cartilage-hair hypoplasia. *J. Med. Genet.* 32 (1), 39–43.
- Mäkitie, O., Vakkilainen, S., 1993. In: Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R. A., Wallace, S.E., Amemiya, A., curatori GeneReviews® (Eds.), *Cartilage-Hair Hypoplasia – Anaxetic Dysplasia Spectrum Disorders*. University of Washington, Seattle, WA [Internet].
- Mäkitie, O., Kaitila, I., 1993. Cartilage-hair hypoplasia—clinical manifestations in 108 Finnish patients. *Eur. J. Pediatr.* 152 (3), 211–217.
- Nakashima, E., Tran, J.R., Welting, T.J.M., Pruijn, G.J.M., Hirose, Y., Nishimura, G., et al., 2007. Cartilage hair hypoplasia mutations that lead to RMRP promoter inefficiency or RNA transcript instability. *Am. J. Med. Genet.* 143A (22), 2675–2681.
- Omenn, G.S., 1965. Familial reticuloendotheliosis with eosinophilia. *N. Engl. J. Med.* 273, 427–432.
- Ott, H., 2019. Guidance for assessment of erythroderma in neonates and infants for the pediatric immunologist. *Pediatr. Allergy Immunol. Off. Pub. Eur. Soc. Pediatr. Allergy Immunol.* 30 (3), 259–268.
- Pruszkowski, A., Bodemer, C., Fraïtag, S., Teillac-Hamel, D., Amor, J.C., de Prost, Y., 2000. Neonatal and infantile erythrodermas: a retrospective study of 51 patients. *Arch. Dermatol.* 136 (7), 875–880.
- Ridnapää, M., van Eenennaam, H., Pelin, K., Chadwick, R., Johnson, C., Yuan, B., et al., 2001. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. *Cell* 104 (2), 195–203.
- Rider, N.L., Morton, D.H., Puffenberger, E., Hendrickson, C.L., Robinson, D.L., Strauss, K. A., 2009. Immunologic and clinical features of 25 Amish patients with RMRP 70 AG cartilage hair hypoplasia. *Clin. Immunol. Orlando Fla* 131 (1), 119–128.
- Roifman, C.M., Gu, Y., Cohen, A., 2006. Mutations in the RNA component of RNase mitochondrial RNA processing might cause Omenn syndrome. *J. Allergy Clin. Immunol.* 117 (4), 897–903.
- Tan, R., BC Children's Hospital Members, Rozmus, J., Turvey, S.E., Biggs, C.M., 2023. Homozygous RMRP promoter duplications cause severely reduced transcript abundance and SCID associated with cartilage hair Hypoplasia. *J. Clin. Immunol.* 43 (6), 1139–1142.
- Thiel, C.T., Horn, D., Zabel, B., Ekici, A.B., Salinas, K., Gebhart, E., et al., 2005. Severely incapacitating mutations in patients with extreme short stature identify RNA-processing endoribonuclease RMRP as an essential cell growth regulator. *Am. J. Hum. Genet.* 77 (5), 795–806.
- Vakkilainen, S., Skoog, T., Einarsson, E., Middleton, A., Pekkinen, M., Öhman, T., et al., 2019a. The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2. *Sci. Rep.* 9 (1), 13758.
- Vakkilainen, S., Taskinen, M., Klemetti, P., Pukkala, E., Mäkitie, O., 2019b. A 30-Year prospective Follow-Up Study reveals risk factors for early death in cartilage-hair Hypoplasia. *Front. Immunol.* 10, 1581.
- Vakkilainen, S., Taskinen, M., Mäkitie, O., 2020. Immunodeficiency in cartilage-hair hypoplasia: pathogenesis, clinical course and management. *Scand. J. Immunol.* 92 (4), e12913.
- Vatanavicharn, N., Visitsunthorn, N., Pho-iam, T., Jirapongsananuruk, O., Pacharn, P., Chokephaibulkit, K., et al., 2010. An infant with cartilage-hair hypoplasia due to a novel homozygous mutation in the promoter region of the RMRP gene associated with chondrodysplasia and severe immunodeficiency. *J. Appl. Genet.* 51 (4), 523–528.
- Villar, J., Cheikh Ismail, L., Victoria, C.G., Ohuma, E.O., Bertino, E., Altman, D.G., et al., 2014. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn cross-sectional study of the INTERGROWTH-21st project. *Lancet Lond. Engl.* 384 (9946), 857–868.

Further Reading

- Arponen, H., Eävalhti, M., Mäkitie, O., 2021. Craniofacial and craniocervical features in cartilage-hair hypoplasia: a radiological Study of 17 patients and 34 controls. *Front. Endocrinol.* 12, 741548.
- Ashby, G.H., Evans, D.I., 1986. Cartilage hair hypoplasia with thrombocytopenic purpura, autoimmune haemolytic anaemia and cell-mediated immunodeficiency. *J. R. Soc. Med.* 79 (2), 113–114.

- Bonafé, L., Schmitt, K., Eich, G., Giedion, A., Superti-Furga, A., 2002. RMRP gene sequence analysis confirms a cartilage-hair hypoplasia variant with only skeletal manifestations and reveals a high density of single-nucleotide polymorphisms. *Clin. Genet.* 61 (2), 146–151.
- de Silva, L.M., Bale, P., de Courcy, J., Brown, D., Knowles, W., 1995. Renal failure due to BK virus infection in an immunodeficient child. *J. Med. Virol.* 45 (2), 192–196.
- Eisner, J.M., Russell, M., 2006. Cartilage hair hypoplasia and multiple basal cell carcinomas. *J. Am. Acad. Dermatol.* 54 (2 Suppl. 1), S8–S10.
- Glass, R.B., Tiffet, C.J., 1999. Radiologic changes in infancy in McKusick cartilage hair hypoplasia. *Am. J. Med. Genet.* 86 (4), 312–315.
- Hermanns, P., Tran, A., Munivez, E., Carter, S., Zabel, B., Lee, B., et al., 2006. RMRP mutations in cartilage-hair hypoplasia. *Am. J. Med. Genet.* 140 (19), 2121–2130.
- Holopainen, E., Vakkilainen, S., Mäkitie, O., 2018. Gynecologic assessment of 19 adult females with cartilage-hair hypoplasia - high rate of HPV positivity. *Orphanet J. Rare Dis.* 13 (1), 207.
- Kelling, C., Goldsmith, L.A., Baden, H.P., 1973. Biophysical and biochemical studies of the hair in cartilage-hair hypoplasia. *Clin. Genet.* 4 (6), 500–506.
- Kukkola, H.L., Utriainen, P., Huttunen, P., Taskinen, M., Mäkitie, O., Vakkilainen, S., 2022. Lymphomas in cartilage-hair hypoplasia - a case series of 16 patients reveals advanced stage DLBCL as the most common form. *Front. Immunol.* 13, 1004694.
- Kwan, A., Manning, M.A., Zollars, L.K., Hoyme, H.E., 2012. Marked variability in the radiographic features of cartilage-hair hypoplasia: case report and review of the literature. *Am. J. Med. Genet.* 158A (11), 2911–2916.
- Le Merrer, A., Maroteaux, P., 1991. Cartilage Hair Hypoplasia in Infancy: a Misleading Chondrodysplasia.
- Lux, S.E., Johnston, R.B., August, C.S., Say, B., Penchaszadeh, V.B., Rosen, F.S., et al., 1970. Chronic neutropenia and abnormal cellular immunity in cartilage-hair hypoplasia. *N. Engl. J. Med.* 282 (5), 231–236.
- McCann, L.J., McPartland, J., Barge, D., Strain, L., Bourn, D., Calonje, E., et al., 2014. Phenotypic variations of cartilage hair hypoplasia: granulomatous skin inflammation and severe T cell immunodeficiency as initial clinical presentation in otherwise well child with short stature. *J. Clin. Immunol.* 34 (1), 42–48.
- Mckusick, V.A., Eldridge, R., Hostetler, J.A., Ruagwit, U., Egeland, J.A., 1965. Dwarfism in the amish. II. CARTILAGE-HAIR hypoplasia. *Bull. Johns Hopkins Hosp.* 116, 285–326.
- Mäkitie, O., 1992. Cartilage-hair hypoplasia in Finland: epidemiological and genetic aspects of 107 patients. *J. Med. Genet.* 29 (9), 652–655.
- Mäkitie, O., Heikkinen, M., Kaitila, I., Rintala, R., 2002. Hirschsprung's disease in cartilage-hair hypoplasia has poor prognosis. *J. Pediatr. Surg.* 37 (11), 1585–1588.
- Mäkitie, O., Marttinen, E., Kaitila, I., 1992a. Skeletal growth in cartilage-hair hypoplasia. A radiological study of 82 patients. *Pediatr. Radiol.* 22 (6), 434–439.
- Mäkitie, O., Perheentupa, J., Kaitila, I., 1992b. Growth in cartilage-hair hypoplasia. *Pediatr. Res.* 31 (2), 176–180.
- Mäkitie, O., Pukkala, E., Teppo, L., Kaitila, I., 1999. Increased incidence of cancer in patients with cartilage-hair hypoplasia. *J. Pediatr.* 134 (3), 315–318.
- Mäkitie, O., Rajantie, J., Kaitila, I., 1992c. Anaemia and macrocytosis—unrecognized features in cartilage-hair hypoplasia. *Acta Paediatr. Oslo Nor* 81 (12), 1026–1029.
- Mäkitie, O.M., Tapanainen, P.J., Dunkel, L., Siimes, M.A., 2001. Impaired spermatogenesis: an unrecognized feature of cartilage-hair hypoplasia. *Ann. Med.* 33 (3), 201–205.
- Moshous, D., Meyts, I., Fraïtag, S., janssen, C.E., Debré, M., 2011. Granulomatous inflammation in cartilage-hair hypoplasia: risks and benefits of anti-TNF- α mAbs. *J. Allergy Clin. Immunol.* 128 (4), 847–853.
- Pierce, G.F., Polmar, S.H., 1982. Lymphocyte dysfunction in cartilage hair hypoplasia. II. Evidence for a cell cycle specific defect in T cell growth. *Clin. Exp. Immunol.* 50 (3), 621–628.
- Polmar, S.H., Pierce, G.F., 1986. Cartilage hair hypoplasia: immunological aspects and their clinical implications. *Clin. Immunol. Immunopathol.* 40 (1), 87–93.
- Riaz, I.B., Faridi, W., Patnaik, M.M., Abraham, R.S., 2019. A systematic review on predisposition to lymphoid (B and T cell) neoplasias in patients with primary immunodeficiencies and immune dysregulatory disorders (inborn errors of immunity). *Front. Immunol.* 10, 777.
- Rönning, O., Myllärniemi, S., Perheentupa, J., 1978. Craniofacial and dental characteristics of cartilage-hair hypoplasia. *Cleft Palate J.* 15 (1), 49–55.
- Roberts, M.A., Arnold, R.M., 1984. Hodgkin's lymphoma in a child with cartilage-hair hypoplasia: case report. *Mil. Med.* 149 (5), 280–281.
- Rozas-Muñoz, E., Blamey-Diaz, R., Gallardo-Olivos, A.M., Jerez, J., Madariaga, J.A., 2024. Extensive and deep granulomatous ulcers as an atypical manifestation of cartilage-hair hypoplasia syndrome: a diagnostic and therapeutic challenge. *Australas. J. Dermatol.* 65 (3), 272–275.
- Sathishkumar, D., Gach, J.E., Ogboli, M., Desai, M., Cole, T., Höglér, W., et al., 2018. Cartilage hair hypoplasia with cutaneous lymphomatoid granulomatosis. *Clin. Exp. Dermatol.* 43 (6), 713–717.
- Singh, A., Krishnan, R., Bhattacharya, M., Pradhan, G., Salzer, U., Kapoor, S., 2013. Cartilage hair hypoplasia and celiac disease: report of an Indian girl with novel genotype. *Indian J. Gastroenterol. Off J. Indian Soc. Gastroenterol.* 32 (6), 409–412.
- Taskinen, M., Ranki, A., Pukkala, E., Jeskanen, L., Kaitila, I., Mäkitie, O., 2008. Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of Non-Hodgkin lymphoma and basal cell carcinoma. *Am. J. Med. Genet.* 146A (18), 2370–2375.
- Toivainen-Salo, S., Kajosaari, M., Piilonen, A., Mäkitie, O., 2008. Patients with cartilage-hair hypoplasia have an increased risk for bronchiectasis. *J. Pediatr.* 152 (3), 422–428.
- Trojak, J.E., Polmar, S.H., Winkelstein, J.A., Hsu, S., Francomano, C., Pierce, G.F., et al., 1981. Immunologic studies of cartilage-hair hypoplasia in the Amish. *Johns Hopkins Med. J.* 148 (4), 157–164.
- Vakkilainen, S., Mäkitie, R., Klemetti, P., Valtä, H., Taskinen, M., Husebye, E.S., et al., 2018. A wide spectrum of Autoimmune manifestations and other symptoms suggesting immune dysregulation in patients with cartilage-hair Hypoplasia. *Front. Immunol.* (9), 2468.
- van der Burgt, I., Haraldsson, A., Oosterwijk, J.C., van Essen, A.J., Weemaes, C., Hamel, B., 1991. Cartilage hair hypoplasia, metaphyseal chondrodysplasia type McKusick: description of seven patients and review of the literature. *Am. J. Med. Genet.* 41 (3), 371–380.
- Williams, M.S., Ettinger, R.S., Hermanns, P., Lee, B., Carlsson, G., Taskinen, M., et al., 2005. The natural history of severe anemia in cartilage-hair hypoplasia. *Am. J. Med. Genet.* 138 (1), 35–40.
- Yasui, Y., Kohno, M., Nishida, S., Shironomae, T., Satomi, M., Kuwahara, T., et al., 2017. Cartilage-hair hypoplasia associated with isolated hypoganglionosis: a case report. *Congenital. Anom.* 57 (1), 32–34.